Prescribing information can be accessed using the link at the top.

ZEPOSIA®Black medical triangle (ozanimod) for ulcerative colitis

ZEPOSIA® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1

A first-in-class oral treatment for UC that selectively targets S1P receptors 1 and 51

Prescribing information can be accessed using the link at the top.

ZEPOSIA®Black medical triangle (ozanimod) for ulcerative colitis

ZEPOSIA® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1

A first-in-class oral treatment for UC that selectively targets S1P receptors 1 and 51

Why target S1P receptors?

By using S1P receptor modulators we can reversibly sequester lymphocytes in lymphoid tissue1,2

Blue icon with arrows pointing outwards, representing a zoom optionPinch & zoom to explore

How does ZEPOSIA work?

Diagram showing ZEPOSIA small molecule bound to S1P receptors 1 and 5 on lymphocytes in a lymphoid organ, alongside an efferent lymphatic veseel and a blood vessel with circulating lymphocytes

Blue icon with arrows pointing outwards, representing a zoom optionPinch & zoom to explore

  • ZEPOSIA targets S1P receptors 1 and 5 to help reduce gut inflammation1-3
  • The mechanism by which ZEPOSIA exerts therapeutic effects in UC is unknown but may involve the reduction of lymphocyte migration into the intestine1
  • ZEPOSIA has minimal or no activity on S1P2, S1P3, and S1P4 receptors1
  • ZEPOSIA has minimal impact on monocytes, natural killer and natural killer T cells, which are all involved in innate immune response – a key component of immunosurveillance against infection and tumours1,15

S1P, sphingosine-1-phosphate; UC, ulcerative colitis.

References

  1. ZEPOSIA (ozanimod) Summary of Product Characteristics, 2023.
  2. Scott FL et al. Br J Pharmacol 2016; 173:1778–1792.
  3. Sandborn WJ et al. N Engl J Med. 2021; 385(14):1280–1291
  4. Peyrin-Biroulet L et al. Autoimmune Rev. 2017;16:495–503.
  5. Schwab SR, Cyster JG. Nat Immunol. 2007;8:1295-1301.
  6. Jaigirdar SA et al. Front Immunol. 2017;8:1627.
  7. Karuppuchamy T et al. Mucosal Immunol. 2017;10:162–171.
  8. Schwab SR et al. Science 2005;309:1735–1739.
  9. Roviezzo F et al. J Pharmacol Exp Ther. 2011;337:830–837.
  10. Danese S et al. J Crohns Colitis 2018;12(suppl 2);S678–S686.
  11. Suh JH et al. Transl Cancer Res. 2015;4(5):469–483.
  12. Proia RL, Hla T. J Clin Invest. 2015;125:1379–1387.
  13. Lucaciu LA et al. Eur J Gastroenterology & Hepatology 2020:32;669-677.
  14. Lamb YN. Drugs 2020;8:841–848.
  15. Harris S et al. Neurol Neuroimmunol Neuroinflamm 2020; 7:e839.

Legal Notice | Privacy Policy

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland-via HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1800 749 749 (Ireland).

© 2024 Bristol-Myers Squibb Company. All rights reserved.
Job: 2084-GB-2300276 Date of Preparation: June 2023